Month: February 2024

Form 8.3 – [LXi REIT PLC – 02 02 2024) – (CGWL)

Written by Customer Service on February 5, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LXi REIT PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Written by Customer Service on February 5, 2024. Posted in Public Companies.

Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company’s patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space. Clearmind’s IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted...

Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company

Written by Customer Service on February 5, 2024. Posted in Public Companies.

Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”). “We look forward to expanding our proprietary topical products into the European region and to be doing so through the utilization of our own international infrastructure for manufacturing. We are confident that through this...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 02 02 2024] – (CGWL)

Written by Customer Service on February 5, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Written by Customer Service on February 5, 2024. Posted in Public Companies.

– Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms. – Pro forma cash and investments expected to fund current operating plan into late 2025. REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private...

One World Products Confirms That Its Colombian Cannabis Operations are Unaffected by Recent Regulatory Developments in Colombia

Written by Customer Service on February 5, 2024. Posted in Public Companies.

Recent Agreements Executed with Smokiez Edibles and the Marley Family’s Kx Family Care Are Expected to Ramp Operations in Early 2024 LAS VEGAS, NV , Feb. 05, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — One World Products, Inc. (the “Company,”) (OTCQB: OWPC), a fully-licensed hemp and cannabis producer in Colombia, today announced that its current business prospects are unaffected by recent regulatory and political hurdles in Colombia. With a business model primarily centered on international markets and medicinal applications, OWP remains insulated from the uncertainties surrounding the domestic Colombian THC market for recreational use. The Company’s products, which include a range of THC solutions provided through medical channels, are derived from cannabinoids sourced from hemp and are fully compliant with current...

Meso Numismatics Announces Intention to Undergo Name Change and Authorized Shares Change

Written by Customer Service on February 5, 2024. Posted in Public Companies.

LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov. About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in...

AMG Reports Financial and Operating Results for the Fourth Quarter and Full Year 2023

Written by Customer Service on February 5, 2024. Posted in Earnings Releases And Operating Results.

Company reports EPS of $5.15, Economic EPS of $6.86 in the fourth quarter of 2023 EPS of $17.42, Economic EPS of $19.48 for the full year 2023Net income (controlling interest) of $673 million, Economic Net Income (controlling interest) of $718 million(i) Completed investment in Ara Partners, a private markets firm specializing in industrial decarbonization, further enhancing AMG’s exposure to secular growth areas Repurchased $574 million in common stock or approximately 10% of our shares outstanding in 2023, inclusive of $225 million accelerated share repurchase programWEST PALM BEACH, Fla., Feb. 05, 2024 (GLOBE NEWSWIRE) — AMG, a leading partner to independent investment management firms globally, today reported its financial and operating results for the fourth quarter and year ended December 31, 2023. Jay C....

Wemade unveils new roadmap for DeFi protocol KLEVA

Written by Customer Service on February 5, 2024. Posted in Public Companies.

Wemade is laying the foundation for the transition of DeFi protocol, KLEVA, to become a native service of the WEMIX3.0 Mainnet. Singapore, Feb. 05, 2024 (GLOBE NEWSWIRE) —Becomes a native service of the WEMIX3.0 Mainnet – new trans-Chain DeFi protocol, KLEVA omni – in Q2 2024 Will offer support for major chains including Arbitrum, Avalanche, BNB Chain, Ethereum, Polygon and Optimism Aligns KLEVA omni with the overall aims and vision of the unagi omnichain initiativeLeading global blockchain firm Wemade is laying the foundation for the transition of DeFi protocol, KLEVA (https://kleva.io/), to become a native service of the WEMIX3.0 Mainnet. Commencing with the Tokenomics restructuring on January 20, 2024, this process will be completed with the unveiling of a new KLEVA as a trans-Chain DeFi protocol, KLEVA...

Descartes Sets Date to Announce Fiscal 2024 Fourth Quarter and Year-End Financial Results

Written by Customer Service on February 5, 2024. Posted in Earnings Releases And Operating Results.

WATERLOO, Ontario and ATLANTA, Feb. 05, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX: DSG) (Nasdaq: DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its fiscal 2024 fourth-quarter and year-end financial results after market close on Wednesday, March 6, 2024. Descartes’ executive management team will hold a conference call to discuss the company’s financial results at 5:30 p.m. ET on Wednesday, March 6. Designated numbers are +1 416 764 8658 or +1 888 886 7786 for North America Toll-Free, using Passcode 26517286#. The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. Phone conference dial-in or webcast login is required approximately 10 minutes beforehand. Replays of the conference...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals